Biologics vs standard therapy for lupus kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 to 65 years old.
- You have been diagnosed with lupus (SLE) and have a confirmed kidney biopsy showing lupus nephritis (type III, IV, or V) in the last 6 months.
- Your lupus is active (SLEDAI score > 6) and you have significant protein in your urine (over 1 gram per day).
- Your kidney function is not too low (eGFR must be at least 45 mL/min/1.73 m²).
- You have not had a serious infection, IV antibiotics, or certain other medical conditions in the past month (like hepatitis, tuberculosis, or recent cancer).
- You are not pregnant or breastfeeding, and you have no known allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.